Unknown

Dataset Information

0

Immunology of EBV-Related Lymphoproliferative Disease in HIV-Positive Individuals


ABSTRACT: Epstein-Bar virus (EBV) can directly cause lymphoproliferative disease (LPD), including AIDS-defining lymphomas such as Burkitt’s lymphoma and other non-Hodgkin lymphomas (NHL), as well as human immunodeficiency virus (HIV)-related Hodgkin lymphoma (HL). The prevalence of EBV in HL and NHL is elevated in HIV-positive individuals compared with the general population. Rates of incidence of AIDS-defining cancers have been declining in HIV-infected individuals since initiation of combination anti-retroviral therapy (cART) use in 1996. However, HIV-infected persons remain at an increased risk of cancers related to infections with oncogenic viruses. Proposed pathogenic mechanisms of HIV-related cancers include decreased immune surveillance, decreased ability to suppress infection-related oncogenic processes and a state of chronic inflammation marked by alteration of the cytokine profile and expanded numbers of cytotoxic T lymphocytes with down-regulated co-stimulatory molecules and increased expression of markers of senescence in the setting of treated HIV infection. Here we discuss the cooperation of EBV-infected B cell- and environment-associated factors that may contribute to EBV-related lymphomagenesis in HIV-infected individuals. Environment-derived lymphomagenic factors include impaired host adaptive and innate immune surveillance, cytokine dysregulation and a pro-inflammatory state observed in the setting of chronic, cART-treated HIV infection. B cell factors include distinctive EBV latency patterns and host protein expression in HIV-associated LPD, as well as B cell-stimulating factors derived from HIV infection. We review the future directions for expanding therapeutic approaches in targeting the viral and immune components of EBV LPD pathogenesis.

SUBMITTER: Shindiapina P 

PROVIDER: S-EPMC7556212 | BioStudies | 2020-01-01

REPOSITORIES: biostudies

Similar Datasets

1000-01-01 | S-EPMC5828429 | BioStudies
2019-01-01 | S-EPMC6328036 | BioStudies
1000-01-01 | S-EPMC5665679 | BioStudies
2006-01-01 | S-EPMC2361178 | BioStudies
2020-01-01 | S-EPMC7535753 | BioStudies
2015-01-01 | S-EPMC5502768 | BioStudies
2013-01-01 | S-EPMC3788758 | BioStudies
2005-09-20 | GSE2414 | GEO
2018-01-01 | S-EPMC5874754 | BioStudies
2010-01-01 | S-EPMC3950937 | BioStudies